


Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A compound of formula (I):



(I)

wherein:

Ring A is a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom; wherein if Ring A contains an additional nitrogen atom that nitrogen may be optionally substituted by R^7 ;

R^1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl or C_{2-6} alkynyl;

p is 0-4; wherein the values of R^1 may be the same or different;

R^2 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, azido, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkanoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, carbocyclyl- R^{34} -, heterocyclyl- R^{35} -, C_{1-6} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl or N,N -(C_{1-6} alkyl) $_2$ sulphamoyl; wherein R^2 independently may be optionally substituted on carbon by one or more R^8 ; or R^2 is $-NHR^9$, $-NR^{10}R^{11}$ or $-OR^{12}$;

q is 0-2; wherein the values of R^2 maybe the same or different;

R^3 is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} alkoxy, C_{1-3} alkanoyl,

N -(C_{1-3} alkyl)amino, N,N -(C_{1-3} alkyl)₂amino, C_{1-3} alkanoylamino, N -(C_{1-3} alkyl)carbamoyl, N,N -(C_{1-3} alkyl)₂carbamoyl, C_{1-3} alkylS(O)_a wherein a is 0 to 2, N -(C_{1-3} alkyl)sulphamoyl or N,N -(C_{1-3} alkyl)₂sulphamoyl; wherein R^3 may be independently optionally substituted on carbon by one or more R^{13} ;

n is 0 to 2, wherein the values of R^3 may be the same or different;

R^4 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl or a carbon-linked heterocyclyl; wherein R^4 may be optionally substituted on carbon by one or more R^{14} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{15} ;

R^5 and R^6 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, C_{3-8} cycloalkyl or a 4-7 membered saturated heterocyclic group; wherein R^5 and R^6 independently of each other may be optionally substituted on carbon by one or more R^{16} ; and wherein if a 4-7 membered saturated heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17} ;

R^7 , R^9 , R^{10} , R^{11} and R^{12} are independently selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{2-6} alkenylsulphonyl, C_{2-6} alkynylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)carbamoyl, carbocyclyl, heterocyclyl, carbocyclyl- R^{18} - or heterocyclyl- R^{19} -; wherein R^7 , R^9 , R^{10} , R^{11} and R^{12} may be independently optionally substituted on carbon by a group selected from R^{20} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by R^{21} ;

R^{14} and R^{20} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{2-6} alkenyloxy, C_{2-6} alkynyloxy, C_{1-6} alkoxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkoxy C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2,

C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC₁₋₆alkyl-R²²-, heterocyclylC₁₋₆alkyl-R²³-, carbocyclyl-R²⁴- or heterocyclyl-R²⁵-; wherein R¹⁴ and R²⁰ may be independently optionally substituted on carbon by one or more R²⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁷;

R¹⁸, R¹⁹, R²², R²³, R²⁴, R²⁵, R³⁴ or R³⁵ are independently selected from -O-, -N(R²⁸)-, -C(O)-, -N(R²⁹)C(O)-, -C(O)N(R³⁰)-, -S(O)_s-, -SO₂N(R³¹)- or -N(R³²)SO₂-; wherein R²⁸, R²⁹, R³⁰, R³¹ and R³² are independently selected from hydrogen or C₁₋₆alkyl and s is 0-2;

R¹⁵, R¹⁷, R²¹ and R²⁷ are independently selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R¹⁵, R¹⁷, R²¹ and R²⁷ independently of each other may be optionally substituted on carbon by one or more R³³; and

R⁸, R¹³, R¹⁶, R²⁶ and R³³ are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 2 (currently amended): A compound of formula (I) as claimed in claim 1 wherein:

Ring A is a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen or oxygen atom; wherein if Ring A contains an additional nitrogen atom that nitrogen may be optionally substituted by R⁷; wherein

R⁷ is selected from C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₂₋₆alkenylsulphonyl, carbocyclyl-R¹⁸- or heterocyclyl-R¹⁹-; wherein R⁷ may be independently optionally substituted

on carbon by a group selected from R²⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by R²¹;

R¹⁸ and R¹⁹ are -C(O)-;

R²⁰ is selected from halo, cyano, hydroxy, C₁₋₆alkoxy, C₂₋₆alkynyloxy, C₁₋₆alkanoyloxy, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a wherein a is 2 or heterocyclyl; wherein R²⁰ may be optionally substituted on carbon by one or more R²⁶;

R²¹ is C₁₋₆alkyl; and

R²⁶ is hydroxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 3 (currently amended): A compound of formula (I) as claimed in either claim 1 or claim 2 wherein R¹ is halo or C₁₋₆alkyl or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 4 (currently amended): A compound of formula (I) as claimed in claim 1 or any one of claims 1-3 wherein p is 0 or 1 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 5 (currently amended): A compound of formula (I) as claimed in claim 1 or any one of claims 1-4 wherein:

R² is selected from hydroxy, amino, azido, C₁₋₆alkyl, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)₂carbamoyl, carbocyclyl-R³⁴-, -NHR⁹ or -O-R¹²;

R⁹ and R¹² are independently selected from C₁₋₆alkanoyl or C₁₋₆alkylsulphonyl; wherein R⁹ and R¹² may be independently optionally substituted on carbon by a group selected from R²⁰;

R²⁰ is hydroxy; and

R³⁴ is -N(R²⁹)C(O)-; wherein R²⁹ is hydrogen;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 6 (currently amended): A compound ~~of~~ formula (I) as claimed in claim 1 ~~any one of claims 1-5~~ wherein R³ is halo or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester thereof~~.

Claim 7 (currently amended): A compound ~~of~~ formula (I) as claimed in claim 1 ~~any one of claims 1-6~~ wherein n is 0 or 1 or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester thereof~~.

Claim 8 (currently amended): A compound ~~of~~ formula (I) as claimed in claim 1 ~~any one of claims 1-7~~ wherein:

R⁴ is C₁₋₆alkyl or carbocyclyl; wherein R⁴ may be optionally substituted on carbon by one or more R¹⁴; wherein

R¹⁴ is carbocyclyl;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester thereof~~.

Claim 9 (currently amended): A compound of formula (I) as claimed in claim 1 ~~any one of claims 1-8~~ wherein:

R⁵ and R⁶ are independently selected from hydrogen or C₁₋₆alkyl; wherein R⁵ and R⁶ independently of each other may be optionally substituted on carbon by one or more R¹⁶; wherein

R¹⁶ is selected from methoxy;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester thereof~~.

Claim 10 (currently amended): A compound of formula (I), ~~as depicted as claimed in~~ claim 1, wherein:

Ring A, R² and q together form piperazin-1-yl, morpholino, 4-mesylpiperazin-1-yl, 4-acetylpiperazin-1-yl, 4-(2-acetoxyacetyl)piperazin-1-yl, 4-(2-hydroxyacetyl)piperazin-1-yl, 4-(2-chloroacetyl)piperazin-1-yl, 4-(2-methoxyacetyl)piperazin-1-yl, (3-methoxypropanoyl)piperazin-1-yl, (3-hydroxy-3-methylbutanoyl)piperazin-1-yl, (3-hydroxy-2,2-dimethylpropanoyl)piperazin-1-yl,

((R)-3-methyl-2-hydroxybutanoyl)piperazin-1-yl,
((S)-3-methyl-2-hydroxybutanoyl)piperazin-1-yl,
4-(2-dimethylaminoacetyl)piperazin-1-yl, 4-[2-(dimethylamino)ethylsulphonyl]piperazin-1-yl,
4-[2-(methoxy)ethylsulphonyl]piperazin-1-yl, 4-[2-(hydroxy)ethylsulphonyl]piperazin-1-yl,
4-(cyclopropylcarbonyl)piperazin-1-yl, 4-(1-hydroxycyclopropylcarbonyl)piperazin-1-yl,
4-(1-cyanocyclopropylcarbonyl)piperazin-1-yl, 4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl,
4-((R)-2-hydroxypropanoyl)piperazin-1-yl, 4-((S)-2-hydroxypropanoyl)piperazin-1-yl,
4-((R)-2-methoxypropanoyl)piperazin-1-yl, 4-((S)-2-methoxypropanoyl)piperazin-1-yl,
4-((R)-tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl,
4-((S)-tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl, 4-(isobutyryl)piperazin-1-yl,
4-((R)-2-hydroxybutanoyl)piperazin-1-yl, 4-((S)-2-hydroxybutanoyl)piperazin-1-yl,
(R)-3-acetylaminopyrrolidin-1-yl, (S)-3-acetylaminopyrrolidin-1-yl,
(R)-2-(cyclopropylaminocarbonyl)pyrrolidin-1-yl, (R)-2-(*N*-methylcarbamoyl)pyrrolidin-1-yl,
(S)-2-(*N,N*-dimethylcarbamoyl)pyrrolidin-1-yl, 4-(ethenylsulphonyl)piperazin-1-yl,
4-[2-(2-propyn-1-yloxy)acetyl]piperazin-1-yl, 4-(tetrahydrofuran-3-ylcarbonyl)piperazin-1-yl,
4-(3-dimethylaminopropanoyl)piperazin-1-yl,
4-[2-(*N*-methyl-*N*-hydroxymethylamino)acetyl]piperazin-1-yl,
4-[3-hydroxy-2-(hydroxymethyl)propanoyl]piperazin-1-yl,
4-[2-(1,2,3,4-tetrazol-1-yl)acetyl]piperazin-1-yl, 4-[2-(1,2,3,4-tetrazol-5-yl)acetyl]piperazin-1-yl,
4-(1-methyl-*L*-prolyl)piperazin-1-yl, 4-[2-(mesyl)acetyl]piperazin-1-yl,
4-(2,2-difluoroacetyl)piperazin-1-yl, 4-[2-(pyrrolidin-1-yl)acetyl]piperazin-1-yl,
4-[2-(morpholino)acetyl]piperazin-1-yl, 4-[2-(diethylamino)acetyl]piperazin-1-yl,
4-(propionyl)piperazin-1-yl, 4-(3-hydroxypropionyl)piperazin-1-yl,
4-[2-(azetidin-1-yl)acetyl]piperazin-1-yl, (R)-3-aminopyrrolidin-1-yl,
(S)-3-aminopyrrolidin-1-yl, (3*R*,5*S*)-4-acetyl-3,5-dimethylpiperazin-1-yl,
(2*S*,5*R*)-4-acetyl-2,5-dimethylpiperazin-1-yl, (2*RS*,6*SR*)-2,6-dimethylmorpholin-4-yl]phenyl,
3-hydroxyazetidin-1-yl, 3-acetylaminazetidin-1-yl, 3-(2-hydroxyacetylamino)azetidin-1-yl,
3-mesyloxyaminazetidin-1-yl, 3-mesyloxyazetidin-1-yl, 3-azidoazetidin-1-yl, 3-aminoazetidin-1-yl,
(3*R*)-3-[[2-(2*S*)-2-hydroxypropanoyl]amino]pyrrolidin-1-yl,
(3*S*)-3-[[2-(2*S*)-2-hydroxypropanoyl]amino]pyrrolidin-1-yl,

(3*S*)-3-(glycoloylamino)pyrrolidin-1-yl and (3*R*)-3-(glycoloylamino)pyrrolidin-1-yl;

R¹ is fluoro, chloro or methyl;

p is 0 or 1;

R² is selected from hydroxy, amino, azido, methyl, *N*-methylcarbamoyl, *N,N*-dimethylcarbamoyl, acetamido, {[*(2S)*-2-hydroxypropanoyl]amino}, glycoloylamino, mesylamino, 2-hydroxyacetamido, mesyloxy or *N*-cyclopropylcarbamoyl.

q is 0-2; wherein the values of R² maybe the same or different;

R³ is 5-fluoro or 5-chloro;

n is 0 or 1;

R⁴ is ethyl, isopropyl, isobutyl, cyclobutyl or cyclopropylmethyl; and

R⁵ and R⁶ are independently selected from hydrogen, methyl, ethyl, methoxymethyl, propyl;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester thereof.~~

Claim 11 (currently amended): A compound of formula (I), ~~as depicted~~ as claimed in claim 1, selected from:

2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-5-fluoropyrimidine hydrochloride;

2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidine;

(2*S*)-1-[4-(4-{[5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)piperazin-1-yl]-1-oxopropan-2-ol;

2-{4-(morpholino)anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-5-fluoropyrimidine

2-{4-[4-(acetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-5-fluoropyrimidine;

2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidine;

5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{4-[4-(methoxyacetyl)piperazin-1-yl]phenyl}pyrimidin-2-amine;

N-[4-(4-acetylpiperazin-1-yl)-3-fluorophenyl]-5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine;


N-[4-(4-acetylpiperazin-1-yl)-3-fluorophenyl]-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine; and

(2*R*)-1-[4-(4-{[5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)piperazin-1-yl]-1-oxopropan-2-ol;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester thereof.~~


Claim 12 (currently amended): A process for preparing a compound of formula (I), as claimed in claim 1 ~~any one of claims 1-11~~, or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester thereof~~, which process, wherein variable groups are, unless otherwise specified, as defined claim 1, comprises of:

Process a) reaction of a pyrimidine of formula (II):



(II)


wherein L is a displaceable group; with an aniline of formula (III):



(III)


or

Process b) reacting a compound of formula (IV):



(IV)


with a compound of formula (V):



(V)


wherein T is O or S; R^x may be the same or different and is selected from C_{1-6} alkyl; or

Process c) reacting a pyrimidine of formula (VI):



(VI)


wherein X is a displaceable group; with a heterocyclyl of formula (VII):



(VII)


or

Process d) for compounds of formula (I); reacting a pyrimidine of formula (VIII)



(VIII)

with a compound of formula (IX):



(IX)

where Y is a displaceable group;

and thereafter ~~if necessary~~ optionally:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups; and/or
- iii) forming a pharmaceutically acceptable salt ~~or in vivo hydrolysable ester.~~

Claim 13 (currently amended): A pharmaceutical composition which comprises a

compound of formula (I) or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier.

Claim 14 (currently amended): A compound of the formula (I), or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, for use in a method of treatment of the human or animal body by therapy.

Claim 15 (currently amended): A compound of the formula (I), or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, for use as a medicament.

Claims 16-20 (canceled)

Claim 21 (currently amended): A method for producing a cell cycle inhibitory, anti-cell-proliferation, effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), as claimed in ~~any one of claims 1-11~~ claim 1.

Claim 22 (currently amended): A method of treating cancers, solid tumours and leukaemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1.

Claim 23 (currently amended): A method of treating cancer in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an

effective amount of a compound of formula (I) or a pharmaceutically acceptable salt ~~or in vivo hydrolysable ester thereof~~, as claimed in ~~any one of claims 1-11~~ claim 1.

Claim 24 (original): A method as claimed in claim 23 wherein said cancer is leukaemia, breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, cancer of the pancreas, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.

Claim 25 (currently amended): A method of producing a CDK inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt ~~or in vivo hydrolysable ester thereof~~, as claimed in ~~any one of claims 1-11~~ claim 1.

Claim 26 (currently amended): A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt ~~or in vivo hydrolysable ester thereof~~, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a cell cycle inhibitory, anti-cell-proliferation, effect in a warm-blooded animal such as man.

Claim 27 (currently amended): A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt ~~or in vivo hydrolysable ester thereof~~, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of cancers, solid tumours and leukaemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal such as man.

Claim 28 (currently amended): A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt ~~or in vivo hydrolysable ester~~

thereof, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of cancer in a warm-blooded animal such as man.

Claim 29 (original): A pharmaceutical composition as claimed in claim 28 wherein said cancer is leukaemia, breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, cancer of the pancreas, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.

Claim 30 (currently amended): A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a CDK inhibitory effect in a warm-blooded animal such as man.